Premium
The effect of deferiprone (L 1 ) and desferrioxamine on myelopoiesis using a liquid culture system
Author(s) -
AlRefaie F. N.,
Wilkes S.,
Wonke B.,
Hoffbrand A. V.
Publication year - 1994
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1994.tb04892.x
Subject(s) - myelopoiesis , deferiprone , toxicity , medicine , gastroenterology , pharmacology , chelation , chemistry , deferoxamine , haematopoiesis , biology , genetics , stem cell , organic chemistry
Summary. Agranulocytosis was observed in a 63‐year‐old patient with myelodysplasia 6 weeks after commencing chelation with the oral iron chelator deferiprone (1,2‐dimethyl‐3‐hydroxypyrid‐4‐one, L 1 ) at a daily dose of 79 mg/kg. Using a liquid culture system no difference was observed when L 1 toxicity to normal and patient myelopoiesis was compared (IC 50 : 150 v 172 μM respectively). L 1 was found to be less toxic than desferrioxamine (DFX) (IC 50 : 150 u 9 μM respectively) to normal myelopoiesis. Delayed addition of iron to myeloid cultures containing an inhibitory concentration of L 1 or DFX was associated with reversal of chelator‐induced inhibition of myelopoiesis up to 6 h but not after 24 h. Further studies are needed to determine the incidence and elucidate the pathogenesis of agranulocytosis associated with L 1 therapy.